Khella (Mycobacterium avium Complex) Infection - Causes, Treatment & When to See a Doctor

```html

What is Khella (Mycobacterium avium Complex) Infection?

Khella, more commonly referred to as an infection caused by the Mycobacterium avium complex (MAC), is a disease produced by a group of non‑tuberculous mycobacteria (NTM) that live in soil, water, and vegetation. While MAC organisms are generally harmless to people with healthy immune systems, they can cause chronic lung disease, disseminated infection, or skin‑and‑soft‑tissue disease in those who are immunocompromised, have underlying lung conditions, or have had prior lung surgery. The term “Khella” is used in some regions (especially in parts of Africa and the Middle East) to describe the clinical syndrome produced by MAC, particularly when it presents with cough, fever, weight loss, and fatigue.

Key points:

• MAC includes Mycobacterium avium and Mycobacterium intracellulare.
• It is an opportunistic pathogen—most infections occur in people with weakened immunity.
• The bacteria grow slowly, often taking weeks to appear on culture, which can delay diagnosis.
• Both pulmonary and disseminated forms exist; the latter is more common in advanced HIV/AIDS.

Common Causes

MAC infection does not have a single “cause” in the same way that a virus does. Instead, several situations increase exposure or reduce the body’s ability to control the bacteria. The most common predisposing factors include:

• Advanced HIV infection (CD4 count < 50 cells/µL).
• Chronic obstructive pulmonary disease (COPD) or bronchiectasis.
• Cystic fibrosis.
• Prior lung resection or transplantation.
• Use of immunosuppressive medications (e.g., corticosteroids, TNF‑α inhibitors, biologics).
• Silicosis or other occupational lung diseases.
• Age > 60 years – immune function naturally declines with age.
• Exposure to contaminated water sources (e.g., hot tubs, municipal water systems, showerheads).
• Living in areas with high environmental mycobacterial load (certain rural or mountainous regions).
• Underlying malnutrition or chronic systemic illness (e.g., diabetes, chronic kidney disease).

Associated Symptoms

The clinical picture varies with the site of infection.

Pulmonary MAC (the most common form)

• Persistent cough – often productive of sputum that may be clear, white, or occasionally blood‑tinged.
• Shortness of breath, especially on exertion.
• Fatigue and generalized weakness.
• Weight loss or loss of appetite.
• Low‑grade fever and night sweats (less common than in tuberculosis).
• Chest discomfort or “tightness.”

Disseminated MAC (usually HIV‑related)

• Fever that may be persistent or intermittent.
• Profound weight loss and anorexia.
• Anemia, causing fatigue and pallor.
• Enlarged lymph nodes, spleen, or liver (hepatosplenomegaly).
• Skin lesions – papules, nodules, or ulcers that may ulcerate and drain.
• Diarrhea or abdominal pain if the gastrointestinal tract is involved.

Skin & Soft‑Tissue MAC

• Non‑healing wound or ulcer, often after trauma or surgery.
• Granulomatous nodules that may become tender.
• Swelling and erythema around the lesion.

When to See a Doctor

Because MAC infections develop slowly, symptoms may be dismissed as “just a cold” or “age‑related.” Seek medical attention promptly if you experience any of the following:

• Cough lasting longer than 3 weeks, especially with sputum production.
• Unexplained weight loss > 5 % of body weight over a month.
• Fever, night sweats, or chills that persist for more than a week.
• Shortness of breath that worsens or interferes with daily activities.
• New or worsening skin lesions that do not heal within 2 weeks.
• Feeling unusually fatigued despite adequate rest.
• Known immunocompromising condition (e.g., HIV, organ transplant) plus any of the above symptoms.

Diagnosis

Diagnosing MAC infection requires a combination of clinical suspicion, imaging, and microbiologic testing.

Step‑by‑step approach

1. Medical History & Physical Exam – Physician assesses risk factors (HIV status, lung disease, exposures) and looks for characteristic findings.
2. Chest Radiography – May show nodular infiltrates, bronchiectasis, or cavitary lesions, especially in the upper lobes.
3. High‑Resolution CT (HRCT) Scan – Provides detailed view of bronchiectasis, tree‑in‑bud patterns, or nodules.
4. Microbiologic Samples
   • Sputum: At least three early‑morning sputum cultures, or induced sputum, are recommended.
   • Bronchoscopy with BAL (bronchoalveolar lavage) if sputum is negative but suspicion remains.
   • Biopsy of lung tissue when imaging suggests disease but cultures are inconclusive.
5. Laboratory Tests for Disseminated Disease
   • Blood cultures (often require special mycobacterial media).
   • Serum CD4 count and HIV viral load if HIV‑positive.
   • Liver function tests, CBC, and inflammatory markers (CRP, ESR).
6. Pathology – Histopathology may show granulomatous inflammation with acid‑fast bacilli.

According to the 2020 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines, diagnosis of pulmonary MAC requires both clinical (symptoms, radiographic abnormalities) and microbiologic criteria (positive cultures from ≥ two separate sputum specimens or one bronchoscopic specimen).

Treatment Options

Treatment is prolonged, often 12 months or more, and must be individualized based on disease severity, site of infection, and patient tolerance.

Medical Therapy

1. First‑Line Antibiotic Regimen (Pulmonary MAC)
   • Azithromycin 500 mg daily OR Clarithromycin 500 mg twice daily.
   • Ethambutol 15 mg/kg daily (dose adjusted for renal function).
   • Rifampin 600 mg daily (or Rifabutin 300 mg daily if drug interactions are a concern).

   All three drugs are given together for at least 12 months after sputum cultures become negative.

2. Alternative or Add‑On Agents (used when resistance, intolerance, or severe disease)
   • Amikacin (intravenous or inhaled) – especially for severe or disseminated disease.
   • Clofazimine – useful in multidrug‑resistant MAC.
   • Linezolid or Moxifloxacin – considered in refractory cases.
3. Disseminated MAC (HIV‑positive)
   • Azithromycin 500 mg daily + Ethambutol 15 mg/kg daily + Rifabutin 300 mg daily.
   • Initiate antiretroviral therapy (ART) as soon as feasible; immune recovery greatly improves outcomes.
4. Duration
   • Pulmonary disease – minimum 12 months after conversion to negative cultures.
   • Disseminated disease – ≥ 12 months and continued until immune reconstitution (CD4 > 100 cells/µL) and clinical response.

Adjunctive & Home‑Based Measures

• Chest physiotherapy & postural drainage to aid sputum clearance (especially in bronchiectasis).
• Smoking cessation – smoking impairs mucociliary clearance and worsens lung injury.
• Nutritional support – high‑protein, calorie‑dense diet to counterweight loss.
• Hydration – thin secretions are easier to expectorate.
• Vaccinations (influenza, pneumococcal) to reduce secondary infections.
• Regular follow‑up with pulmonary function tests to monitor disease progression.

Prevention Tips

Because MAC is ubiquitous in the environment, total avoidance is impossible, but risk can be minimized:

• Water Safety
  • Avoid using hot tubs, whirlpools, or poorly maintained pools if you are immunocompromised.
  • Prefer filtered or boiled water for drinking and for nasal rinses; avoid “shower‑head” aerosol exposure.
• Respiratory Health
  • Quit smoking and limit exposure to second‑hand smoke.
  • Use humidifiers with distilled water and clean them regularly to prevent bacterial buildup.
• Immunologic Care
  • Maintain optimal control of HIV (adherence to ART) and other chronic illnesses.
  • Discuss prophylactic macrolide therapy with your doctor if you have advanced COPD or bronchiectasis and frequent exacerbations.
• Environmental Precautions
  • Wear a mask when gardening, soil‑working, or cleaning dusty environments.
  • Avoid inhaling aerosolized water from decorative fountains or poorly maintained air‑conditioning units.

Emergency Warning Signs

---

References

• American Thoracic Society & Infectious Diseases Society of America. "Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases." Clin Infect Dis. 2020;71(4): e1‑e84.
• Cleveland Clinic. “Mycobacterium Avium Complex (MAC) Infection.” Updated 2023. https://my.clevelandclinic.org
• Mayo Clinic. “Mycobacterium avium complex (MAC) infection.” Accessed May 2024. https://www.mayoclinic.org
• World Health Organization. “NTM Disease: Global Epidemiology and Control.” 2022. https://www.who.int
• CDC. “NTM (Nontuberculous Mycobacterial) Infections.” Updated 2023. https://www.cdc.gov
• National Institutes of Health, National Institute of Allergy and Infectious Diseases. “Mycobacterium avium complex.” 2022.

```